Nuvation Bio Inc. (NUVB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Nuvation Bio reported revenue of $62.9M, up 699.0% from $7.9M the year before. Net income was -$204.6M (a -325.3% net margin), or -$0.60 per diluted share. Operating margin was -338.7%. Operating activities generated -$173.4M of cash, leaving -$173.4M of free cash flow. At fiscal year end, Nuvation Bio held $594.8M in total assets against $289.1M in total liabilities, including $164.1M of cash and equivalents.
Open the full interactive Nuvation Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Nuvation Bio Key Stats
| Share Price | $4.72 |
|---|---|
| Market Cap | $1.65B |
| Revenue YoY Growth | +699.0% |
| 52-Week Range | $3.41 – $9.54 |
| Shares Outstanding | 348.8 million (basic, 2026 Q2) |
Nuvation Bio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.9M | $62.9M |
| Cost of Goods Sold | — | — | — | $7.1M | — |
| Gross Profit | — | — | — | $795,000 | — |
| Operating Income | -$93.3M | -$119.7M | -$99.8M | -$592.6M | -$213.1M |
| Pre-Tax Income | -$86.8M | -$104.2M | -$75.8M | -$567.9M | -$204.6M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$86.8M | -$104.2M | -$75.8M | -$567.9M | -$204.6M |
| Diluted EPS | -$0.44 | -$0.48 | -$0.35 | -$2.11 | -$0.60 |
Nuvation Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13.1M | $41.9M | $83.2M | $31.7M |
| Net Income | -$55.8M | -$36.6M | $5.4M | -$62.8M |
| Diluted EPS | -$0.16 | -$0.11 | $0.01 | -$0.18 |
Nuvation Bio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $132.4M | $101.1M | $42.6M | $35.7M | $164.1M |
| Current Assets | $772.1M | $667.3M | $616.4M | $526.3M | $571.5M |
| Total Assets | $776.2M | $672.1M | $621.5M | $540.6M | $594.8M |
| Current Liabilities | $16.9M | $13.2M | $14.0M | $58.2M | $82.2M |
| Total Long-Term Debt | — | — | — | — | $47.2M |
| Total Liabilities | $30.2M | $17.1M | $16.4M | $76.8M | $289.1M |
| Shareholders' Equity | $746.0M | $655.1M | $605.1M | $463.8M | $305.7M |
Nuvation Bio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
| Cash From Investing | -$454.7M | $63.5M | $8.9M | $122.7M | $99.5M |
| Cash From Financing | $625.5M | $1.3M | $628,000 | $331,000 | $202.5M |
| Free Cash Flow | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
Figures from Nuvation Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nuvation Bio financials page for every line item.
Nuvation Bio Company Profile
| Ticker | NUVB |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001811063 |
Frequently Asked Questions
What was Nuvation Bio's revenue in fiscal 2025?
Nuvation Bio (NUVB) reported revenue of $62.9M for fiscal 2025.
What is Nuvation Bio's annual revenue history?
Nuvation Bio's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $7.9M; 2025: $62.9M.
What was Nuvation Bio's net income in fiscal 2025?
Nuvation Bio reported net income of -$204.6M for fiscal 2025.
What was Nuvation Bio's earnings per share (EPS) in fiscal 2025?
Nuvation Bio's diluted EPS was -$0.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Nuvation Bio generate in fiscal 2025?
Nuvation Bio generated -$173.4M of free cash flow in fiscal 2025.
What was Nuvation Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Nuvation Bio reported revenue of $31.7M.
How much debt does Nuvation Bio have?
Nuvation Bio reported $47.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Nuvation Bio are outstanding?
Nuvation Bio reported a weighted average of 348.8 million basic shares outstanding in 2026 Q2.
What is Nuvation Bio's market cap?
Based on its latest closing price, Nuvation Bio (NUVB) has a market capitalization of about $1.65B.
When does Nuvation Bio's fiscal year end?
Nuvation Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Nuvation Bio headquartered?
Nuvation Bio lists its business address in New York, New York in its SEC filings.